PMID- 38401847
OWN - NLM
STAT- MEDLINE
DCOM- 20240320
LR  - 20240320
IS  - 1872-8294 (Electronic)
IS  - 0169-409X (Linking)
VI  - 207
DP  - 2024 Apr
TI  - Interactions between nanoparticles and pathological changes of vascular in 
      Alzheimer's disease.
PG  - 115219
LID - S0169-409X(24)00041-3 [pii]
LID - 10.1016/j.addr.2024.115219 [doi]
AB  - Emerging evidence suggests that vascular pathological changes play a pivotal role 
      in the pathogenesis of Alzheimer's disease (AD). The dysfunction of the cerebral 
      vasculature occurs in the early course of AD, characterized by alterations in 
      vascular morphology, diminished cerebral blood flow (CBF), impairment of the 
      neurovascular unit (NVU), vasculature inflammation, and cerebral amyloid 
      angiopathy. Vascular dysfunction not only facilitates the influx of neurotoxic 
      substances into the brain, triggering inflammation and immune responses but also 
      hampers the efflux of toxic proteins such as Abeta from the brain, thereby 
      contributing to neurodegenerative changes in AD. Furthermore, these vascular 
      changes significantly impact drug delivery and distribution within the brain. 
      Therefore, developing targeted delivery systems or therapeutic strategies based 
      on vascular alterations may potentially represent a novel breakthrough in AD 
      treatment. This review comprehensively examines various aspects of vascular 
      alterations in AD and outlines the current interactions between nanoparticles and 
      pathological changes of vascular.
CI  - Copyright (c) 2024 Elsevier B.V. All rights reserved.
FAU - Lei, Ting
AU  - Lei T
AD  - Key Laboratory of Drug-Targeting and Drug Delivery System of the Education 
      Ministry and Sichuan Province, West China School of Pharmacy, Mental Health 
      Center and National Chengdu Center for Safety Evaluation of Drugs, West China 
      Hospital, Sichuan University, Chengdu 610041, China.
FAU - Yang, Zixiao
AU  - Yang Z
AD  - Key Laboratory of Drug-Targeting and Drug Delivery System of the Education 
      Ministry and Sichuan Province, West China School of Pharmacy, Mental Health 
      Center and National Chengdu Center for Safety Evaluation of Drugs, West China 
      Hospital, Sichuan University, Chengdu 610041, China.
FAU - Li, Hanmei
AU  - Li H
AD  - School of Food and Biological Engineering, Chengdu University, Chengdu 610106, 
      China.
FAU - Qin, Meng
AU  - Qin M
AD  - Key Laboratory of Drug-Targeting and Drug Delivery System of the Education 
      Ministry and Sichuan Province, West China School of Pharmacy, Mental Health 
      Center and National Chengdu Center for Safety Evaluation of Drugs, West China 
      Hospital, Sichuan University, Chengdu 610041, China. Electronic address: 
      qinmeng212@scu.edu.cn.
FAU - Gao, Huile
AU  - Gao H
AD  - Key Laboratory of Drug-Targeting and Drug Delivery System of the Education 
      Ministry and Sichuan Province, West China School of Pharmacy, Mental Health 
      Center and National Chengdu Center for Safety Evaluation of Drugs, West China 
      Hospital, Sichuan University, Chengdu 610041, China. Electronic address: 
      gaohuile@scu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240223
PL  - Netherlands
TA  - Adv Drug Deliv Rev
JT  - Advanced drug delivery reviews
JID - 8710523
RN  - 0 (Amyloid beta-Peptides)
SB  - IM
MH  - Humans
MH  - *Alzheimer Disease/drug therapy/metabolism
MH  - Amyloid beta-Peptides/metabolism
MH  - Brain/pathology
MH  - *Nanoparticles
MH  - Inflammation
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - Drug delivery
OT  - Nanoparticles
OT  - Vascular dysfunction
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/02/25 00:42
MHDA- 2024/03/20 06:45
CRDT- 2024/02/24 19:18
PHST- 2023/10/30 00:00 [received]
PHST- 2024/02/16 00:00 [revised]
PHST- 2024/02/20 00:00 [accepted]
PHST- 2024/03/20 06:45 [medline]
PHST- 2024/02/25 00:42 [pubmed]
PHST- 2024/02/24 19:18 [entrez]
AID - S0169-409X(24)00041-3 [pii]
AID - 10.1016/j.addr.2024.115219 [doi]
PST - ppublish
SO  - Adv Drug Deliv Rev. 2024 Apr;207:115219. doi: 10.1016/j.addr.2024.115219. Epub 
      2024 Feb 23.